Eiger BioPharmaceuticals, Inc.

Report azionario OTCPK:EIGR.Q

Capitalizzazione di mercato: US$12.6m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Eiger BioPharmaceuticals Crescita futura

Criteri Future verificati 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Eiger BioPharmaceuticals.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Biotechs crescita degli utili25.3%
Tasso di crescita dei ricavin/a
Rendimento futuro del capitale proprion/a
Copertura analitica

None

Ultimo aggiornamenton/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Articolo di analisi • Apr 01

Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shareholders that were waiting for something to happen have been dealt a...
Articolo di analisi • Jan 04

The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shareholders won't be pleased to see that the share price has had a very...
Articolo di analisi • Dec 20

Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

The latest analyst coverage could presage a bad day for Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ), with the...
Articolo di analisi • Nov 09

Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Shareholders in Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) may be thrilled to learn that the analysts have just...
Articolo di analisi • Oct 06

Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Seeking Alpha • Oct 05

Eiger sheds ~20% on abandonment of EUA request for COVID therapy

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a biotech focused on rare and ultra-rare diseases, slipped ~20% pre-market Wednesday after announcing it would not seek an emergency use authorization (EUA) application in the U.S. for COVID-19 therapy peginterferon lambda. The decision followed a pre-EUA meeting the company had requested from the FDA. The agency denied the request citing issues in an investigator-sponsored trial designed to assess different therapeutic agents, including peginterferon, in non-hospitalized patients with mild-to-moderate COVID-19. FDA has determined that “any authorization request based on these data is unlikely to meet the statutory criteria for issuance of an EUA in the current context of the pandemic,” the company said. Instead, the agency has suggested that EIGR consider requesting an end-of-Phase 2 meeting to run a company-sponsored pivotal trial targeted at a Biologics License Application (BLA). EIGR is weighing the next steps, including strategic options to advance peginterferon lambda against respiratory viral agents, including COVID-19. Read: In September, the FDA updated its COVID-19 test policy to cut the number of reviews of EUA requests for diagnostic tests.
Seeking Alpha • Sep 06

Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy

The shares of commercial-stage biotech Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) fell ~21% in the pre-market Tuesday after the company announced that the FDA is uncertain about the regulatory path for COVID-19 therapy peginterferon lambda. The update comes after the company's meeting with the regulator regarding the Phase 3 TOGETHER study for peginterferon lambda aimed at its emergency use authorization (EUA). Following the meeting, the FDA has indicated its uncertainty if the company can meet the requirements for a EUA submission for peginterferon lambda. However, EIGR remains in talks with the FDA as the regulator indicated its intention to consider any new data from the TOGETHER trial to support a EUA while the company plans to further develop the candidate in COVID-19.
Seeking Alpha • Jul 26

Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst

European Commission granted marketing authorization for Zokinvy (lonafarnib) for the treatment of patients with progeria on July 20, 2022. Results from the phase 3 D-LIVR study using Lonafarnib for the treatment of patients with Hepatitis Delta Virus are expected by end of 2022. In March of 2022, a single dose of peginterferon Lambda for Covid-19, reduced the risk of hospitalization or ER visits greater than 6 hours by 50% in a predominantly vaccinated population. An Emergency Use Authorization filing from Eiger BioPharmaceuticals to the FDA for peginterferon Lambda for Covid-19 is possible in 2022. Eiger BioPharmaceuticals (EIGR) is a great speculative biotech play to look into. That's because it has a major catalyst for investors to look forward to at the end of 2022. This would be the readout of the phase 3 D-LIVR study, which is using Lonafarnib for the treatment of patients with Hepatitis Delta Virus ((HDV)). There is potential here to eventually possibly obtain approval for two combinations. These combinations include Lonafarnib and ritonavir and in combination with peginterferon alfa. In addition, this biotech had already received European approval for its treatment Zokinvy (Lonafarnib) for the treatment of patients with progeria. It is the first and only treatment approved in Europe for this specific indication. In addition, another possible catalyst would be Emergency Use Authorization (EUA) for Peginterferon Lambda for Covid-19 infection. The company is engaging with the FDA and intends to submit an EUA application along with the full set of results from the TOGETHER study. It was done in a predominantly vaccinated patient population, so it remains to be seen how well it does if it is ultimately approved. Regardless, I believe EUA could act as a trade opportunity. These are the reasons why I believe that Eiger BioPharmaceuticals is a great speculative biotech play to look into. Lonafarnib Catalyst Expected End Of 2022 Lonafarnib is in clinical development for the treatment of patients with Hepatitis Delta Virus. Hepatitis Delta Virus ((HDV)) or Hepatitis D is a very small circular RNA virus. It is one of the smallest types of virus that infects humans. However, right off the bat I will tell you that it is rare. Why is it rare? That's because in order for the HDV to infect someone, they also have to be carrying Hepatitis B (HBV). That's right, HDV needs HBV in order to infect a person. That's the only way HDV can replicate in liver cells. Those who may be at risk of getting HDV are those who have gone through many blood transfusions and those who are intravenous types of drug abusers. Symptoms of those who have this virus are as follows: Abdominal type pain Nausea Fatigue Being rare, there are roughly only about less than 200,000 people in the United States who have it. Eiger estimates that an HDV product could be about a >$1 billion per year market opportunity. The good news is that this program is already ongoing and still enrolling patients. This is known as the phase 3 D-LIVR study, which is estimated to enroll about 400 patients total. At least 300 patients will be treated with Lonafarnib. There are going to be two arms in the study as follows: All oral arm of LNF (lonafarnib) boosted with RTV (ritonavir) LNF boosted with RTV combined with pegylated interferon-alfa (PEG IFN-alfa) Each of the 2 arms above are going to be compared to placebo. That means in order for this study to be successful, it just needs to meet the primary endpoint compared to placebo. The composite primary endpoint is twofold as follows: Compare composite virologic and biochemical response rate at end of treatment ((EOT)) in patients who receive 50 mg Lonafarnib/100 mg BID Ritonavir versus patients who receive placebo (over 48 weeks) Compare composite virologic and biochemical response rate at end of EOT in patients who receive 50 mg Lonafarnib/100 mg BID Ritonavir and 180 mcg QW PEG IFN-alfa-2a (over 48 weeks)
Seeking Alpha • Jul 20

European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy

Eiger BioPharmaceuticals (NASDAQ:EIGR) on Wednesday said the European Commission had granted a marketing authorization to its treatment Zokinvy (lonafarnib) for progeria, which is a progressive genetic disorder that causes accelerated aging. The specific indication for which Zokinvy was approved was as a breakthrough therapy in children and young adults with Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies. The European approval for Zokinvy is valid in all 27 EU member states as well as Iceland, Liechtenstein and Norway. EIGR says Zokinvy is the first and only treatment approved in Europe for progeria. The therapy was approved by the U.S. FDA in 2020. EIGR stock +2.8% to $8.73 in early trading.

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Eiger BioPharmaceuticals non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

OTCPK:EIGR.Q - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202316-75-75-75N/A
9/30/202315-87-83-83N/A
6/30/202315-96-89-89N/A
3/31/202315-97-89-89N/A
12/31/202213-97-83-83N/A
9/30/202214-93-78-78N/A
6/30/202213-89-76-76N/A
3/31/202211-86-75-75N/A
12/31/202112-34-71-71N/A
9/30/20219-31-70-70N/A
6/30/20216-24-65-65N/A
3/31/20214-21-60-60N/A
12/31/2020N/A-65-63-63N/A
9/30/2020N/A-63-63-63N/A
6/30/2020N/A-66-64-63N/A
3/31/2020N/A-68-63-62N/A
12/31/2019N/A-70-64-64N/A
9/30/2019N/A-70-61-61N/A
6/30/2019N/A-68-60-60N/A
3/31/2019N/A-61-53-53N/A
12/31/2018N/A-52-43-43N/A
9/30/2018N/A-47-41-41N/A
6/30/2018N/A-39-35-35N/A
3/31/2018N/A-40-36-36N/A
12/31/2017N/A-42-38-38N/A
9/30/2017N/A-44N/A-39N/A
6/30/2017N/A-47N/A-38N/A
3/31/2017N/A-49N/A-45N/A
12/31/2016N/A-47N/A-38N/A
9/30/2016N/A-41N/A-30N/A
6/30/2016N/A-33N/A-25N/A
3/31/2016N/A-22N/A-12N/A
12/31/2015N/A-13N/A-9N/A
9/30/2015N/A-7N/A-6N/A
12/31/2014N/A-2N/A-1N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista EIGR.Q è superiore al tasso di risparmio ( 2.5% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di EIGR.Q cresceranno più velocemente del mercato US

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di EIGR.Q cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di EIGR.Q cresceranno più rapidamente del mercato US.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di EIGR.Q cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di EIGR.Q è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2024/10/02 07:47
Prezzo dell'azione a fine giornata2024/10/01 00:00
Utili2023/12/31
Utili annuali2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Eiger BioPharmaceuticals, Inc. è coperta da 11 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Madhu KumarBaird
Brian SkorneyBaird
Madhu KumarB. Riley Securities, Inc.